Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study

Stopped early · Not applicable

Conditions studied: Diabetes Type 2, Pre-diabetes

In brief

The purpose of this study is to establish safety of biweekly intermittent fasting in the setting of type 2 diabetes mellitus or prediabetes under treatment with non-hypoglycemic agents (e.g. metformin).

Key facts

Study ID

NCT03938441

Run by

gino gaddini

People needed

24

Starts

2019-07-31

Expected to finish

2021-05-28

Last updated by the study team

2021-06-04

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female Active Duty members and DoD beneficiaries ages 18-69
• Diagnosed with Type 2 Diabetes or pre-diabetic
• Prescribed/taking Metformin 500mg to 2000mg daily

You may not qualify if…

• History of recurrent hypoglycemic events on present medication regimen
• Drugs/medication with known increase in hypoglycemic events [Include basal insulin, rapid acting insulin, sulfonylureas, etc.). Metformin is not known to cause hypoglycemia.
• Pregnant
• Medication-induced or secondary diabetes
• Known abnormal hematocrit

Where it is running

• Mike O'Callaghan Military Medical Center — Nellis Air Force Base, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.